Surface-Catalyzed Secondary Nucleation Dominates the Generation of Toxic IAPP Aggregates. by Rodriguez Camargo, Diana C et al.
Surface-Catalyzed Secondary
Nucleation Dominates the Generation
of Toxic IAPP Aggregates
Diana C. Rodriguez Camargo1,2†, Sean Chia2,3†, Joseph Menzies2, Benedetta Mannini 2,3,
Georg Meisl3, Martin Lundqvist 1, Christin Pohl1, Katja Bernfur1, Veronica Lattanzi 1,
Johnny Habchi2,3, Samuel IA Cohen2, Tuomas P. J Knowles3,4, Michele Vendruscolo3 and
Sara Linse1*
1Department of Biochemistry and Structural Biology, Lund University, Lund, Sweden, 2Wren Therapeutics Limited, Clarendon
House, Cambridge, United Kingdom, 3Centre for Misfolding Diseases, Yusuf Hamied Department of Chemistry, University of
Cambridge, Cambridge, United Kingdom, 4Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
The aggregation of the human islet amyloid polypeptide (IAPP) is associated with diabetes
type II. A quantitative understanding of this connection at the molecular level requires that
the aggregation mechanism of IAPP is resolved in terms of the underlying microscopic
steps. Here we have systematically studied recombinant IAPP, with amidated C-terminus
in oxidised form with a disulphide bond between residues 3 and 7, using thioflavin T
fluorescence to monitor the formation of amyloid fibrils as a function of time and IAPP
concentration. We used global kinetic analyses to connect the macroscopic
measurements of aggregation to the microscopic mechanisms, and show that the
generation of new aggregates is dominated by the secondary nucleation of monomers
on the fibril surface. We then exposed insulinoma cells to aliquots extracted from different
time points of the aggregation process, finding the highest toxicity at the midpoint of the
reaction, when the secondary nucleation rate reaches its maximum. These results identify
IAPP oligomers as the most cytotoxic species generated during IAPP aggregation, and
suggest that compounds that target secondary nucleation of IAPP could be most effective
as therapeutic candidates for diabetes type II.
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INTRODUCTION
Currently, approximately 463 million people worldwide have been diagnosed with diabetes which
represents about 9% of the world population (Saeedi et al., 2019). Approximately 4.2 million deaths
in 2019 were linked to diabetes (Saeedi et al., 2020), directly or indirectly caused by complications in
the nerves, kidneys, neurons, visual and cardiovascular systems (Danaei et al., 2014; Huang et al.,
2016). The disease is chronic and requires constant treatment and control, at an annual worldwide
yearly cost of USD 760 billion (Association, 2018). About 90 percent of the cases involve type II
diabetes (Chen et al., 2012), a third of which suffer from late diagnosis aggravating the complications
and hampering treatment. The causes of diabetes, especially type 2, are not clear but there is a strong
correlation with increasing age, ethnicity, genetics (Andrulionytè et al., 2004; Barroso, 2005; Grant
et al., 2009), and obesity (Hutton et al., 1982; Mehnert and Standi, 2000; Knight et al., 2006; Vaiana
et al., 2009). Diabetes causes hyperglycemia and insulin resistance (Mehnert and Standi, 2000). As a
counter response an overproduction of hormones is initiated. These hormones include insulin and
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islet amyloid polypeptide (IAPP), which are co-expressed in the
pancreas and co-secreted from insulin granules (Johnson et al.,
1988; Lukinius et al., 1989). The overproduction of these
hormones, in particular IAPP, is linked to the onset of protein
aggregation and subsequent dysfunction of the β cells (Janson
et al., 1996; Matveyenko and Butler, 2006).
IAPP, also called amylin, is among the most amyloidogenic
peptide hormones known (Opie, 1901). In its biologically active
form, the peptide is 37 amino acid residues long with amidated
C-terminus and an intramolecular disulphide bridge at the
N-terminus (Davidson and Hutton, 1987; Sanke et al., 1988;
Betsholtz et al., 1989; Hutton, 1989; Mosselman et al., 1989; Nishi
et al., 1989;Wang et al., 2001). IAPP aggregates are identified for a
majority (90%) of patients with type 2 diabetes and the true
prevalence is likely to be even higher due to difficulties in
identifying these aggregates in the pancreas (Westermark,
1972; Clark et al., 1988; Betsholtz et al., 1989). Moreover,
IAPP aggregation is a major cause of failed β-cell
transplantation in treatment of type I diabetes (Westermark
et al., 2005). For these reasons, there is considerable interest in
targeting IAPP for diabetes treatment. This will require
knowledge of the molecular pathways underpinning the
aggregation process of IAPP, in particular the correlation
between discrete mechanistic steps and the production of toxic
species that trigger the pathology.
Studies of the aggregation of other disease-related proteins,
such as Aβ (involved in Alzheimer’s disease) and α-synuclein
(involved in Parkinson’s disease), have uncovered the critical role
of secondary nucleation, whereby the surfaces of fibrillar
aggregates catalyse the nucleation of new aggregates from
monomers; this leads to the generation of oligomeric
intermediate species, which are toxic to neurons (Cohen et al.,
2013; Gaspar et al., 2017). In the case of IAPP, the oligomers have
been linked to the death of β cells, and the rate of oligomer
formation appears to be enhanced by plasma and lipid
components (Rodriguez Camargo et al., 2017; Rodeiguez
Camargo et al., 2018). These toxic IAPP oligomers also appear
to be transiently populated during the aggregation process
(Young et al., 2014; Abedini et al., 2016). The existence of a
secondary mechanism in the aggregation of IAPP was previously
proposed from measurements of Tyr fluorescence anisotropy
versus time (Padrick and Miranker, 2002). Surface-catalysed
secondary nucleation has also been inferred for the
proliferation of aggregates of the 10-residue IAPP fragment
SNNFGAILSS(Ruschak and Miranker, 2007). However,
previous studies have used synthetic IAPP peptide or peptide
fragments, and include organic co-solvents such as DMSO and
HFIP, which can significantly affect the rate of aggregation
(Padrick and Miranker, 2002); typically 1–4% DMSO or HFIP
is used, corresponding to 20,000–160,000-fold molar excess
relative to 10 µM IAPP. In addition, the overall rate of
aggregation observed between studies appears to vary over two
orders of magnitude under similar conditions, which might be
attributed to variations in the purity and homogeneity of the
peptide.
In the present work, we have overcome these previous
challenges through the development of a protocol with which
the aggregation kinetics can been monitored starting from highly
pure monomeric recombinant native human IAPP. The protocol
includes the production of recombinant human IAPP peptide to
ensure sequence homogeneity, careful control of the initial
conditions and quality of the peptide using repeated size-
exclusion chromatography for monomer isolation, inertness of
the reaction vessels, quiescent conditions, and total absence of
organic solvents. Employing these factors has resulted in highly
reproducible kinetic data.
To connect the measurements of IAPP aggregation with the
underlying microscopic processes, the kinetic data has been
subjected to global analysis which identify a minimal set of
microscopic steps underlying the overall aggregation process
together with their associated rates and significance. This
strategy reveals that the IAPP aggregation mechanism is
dominated by secondary nucleation of monomers on the fibril
surface. INS-1 832/13 rat insulinoma cells were used to
investigates the effect, after both short (30 min) and long
(24 h) incubation, of samples from different time points of the
aggregation process. The results indicate that oligomeric




In order to study the microscopic processes involved in the
aggregation of IAPP, and to resolve quantitatively the
underlying rate constants of the microscopic processes
underpinning the aggregation reaction, it is essential to
generate highly reproducible experimental measurements of
aggregation over a range of peptide concentrations. Through
optimising the experimental conditions, including the sample
purity, the initial conditions, the inertness of all surfaces involved,
the area of all surfaces and the linearity of the reporter used
(Hellstrand et al., 2010; Meisl et al., 2016), the recorded reaction
profile from such experiments is an accurate reflection of the
molecular processes leading from monomers to fibrils, and the
data can be analysed to reveal information about these processes.
The ability to generate such data has previously been impeded, in
particular, by the difficulty in purifying IAPP and isolating the
monomeric species from other aggregated species. To overcome
these obstacles, we have developed a protocol using successive
rounds of size-exclusion chromatography (SEC). Successive
rounds of SEC guarantee the quality of the measurements of
the aggregation, and allow for subsequent theoretical analysis of
the aggregation mechanism, as previously employed for other
proteins and peptides, such as Aβ (Cohen et al., 2013).
The protocol was developed by exploring a variety of
conditions in terms of buffer composition, pH, temperature
and size-exclusion resin in order to produce IAPP monomers
without excessive losses of the peptide. We found that a rigid allyl
dextran/bisacrylamide matrix (as in the Tricorn 10/300 GL
Sephacryl S-100 HR column) has minimal interaction with
IAPP, which allows for good separation of the monomer from
aggregates and enables isolation of homogeneous samples
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(Figure 1). An initial HiPrep 16/60 Sephacryl S-100 HR SEC
shows the presence of higher-ordered species together with the
monomeric IAPP (Figures 1A,B). Pooling the fractions
containing monomeric IAPP and subjecting them to another
round of size exclusion (using a Tricorn 10/300 GL Sephacryl S-
100), an extremely pure monomeric IAPP sample was obtained.
With this protocol the initial conditions are well-controlled, and
we can study IAPP aggregation kinetics and derive the molecular
mechanism of aggregation (Figures 1C,D).
Reproducible Aggregation Kinetics of
Human IAPP
Starting with pure monomeric IAPP samples, with
concentrations ranging from 2 to 10 µM IAPP, the aggregation
process was studied by monitoring the fluorescence of ThT as a
function of time. In the present work, the aggregation process was
studied at mildly acidic pH (5.3) at an ionic strength of 183 mM
to reflect the physiological environmental conditions inside
the β-cells where IAPP is proposed to aggregate initially
(Hutton, 1982). All experiments were initiated with a
temperature jump from 0 to 37 C.
The aggregation curves of recombinant IAPP presented here
are sigmoidal-like (Figure 2) and qualitatively similar to the data
presented in other publications studying the aggregation of IAPP,
or shorter fragments of IAPP, using tyrosine anisotropy (Padrick
and Miranker, 2002), light scattering (Ruschak and Miranker,
2007) or ANS fluorescence (Kayed et al., 1999). The curves are
also qualitatively similar to those observed for non-amidated
IAPP (Lundqvist et al., 2021). The ThT fluorescence intensity
over time was found to be highly reproducible and dependent on
the initial concentration of IAPP monomers in solution
(Figure 2). Moreover, both the final fluorescence intensity, as
well as the overall rate of aggregation, were found to increase with
the concentration of IAPP in a systematic manner (Figure 2).
The half-time of the aggregation process, t1/2 (time to
formation of half of the final aggregate mass), versus initial
monomer concentration [m]0 was fitted to a power law, t1/2 ∝
[m]0
γ, in order to quantify the concentration dependence of the
aggregation. The scaling exponent γ is related to the reaction
FIGURE 1 | Purification of monomeric recombinant IAPP. (A) Chromatogram from a SEC purification using a HiPrep 16/60 Sephacryl S-100 HR column in 35 mM
sodium acetate buffer, pH 5.3. (B) SDS PAGE using Tris-Tricine gels (10–20% polyacrylamide) of the fractions obtained after SEC as shown in (A). The fractions
containing monomeric IAPP (indicated with asterisks) were collected, combined, and lyophilised for another round of SEC. (C, D) Chromatogram and SDS PAGE from
the second SEC purification using Sephacryl S-100 HR Tricorn 10/300 GL column in 35 mM sodium acetate buffer, pH 5.3.
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FIGURE 2 | Concentration dependence of IAPP aggregation. (A) ThT fluorescence traces following the aggregation of IAPP over time at varying monomer
concentrations, which are represented in different colours. (B) ThT fluorescence amplitude at the end of the aggregation reaction against the IAPP monomer
concentration. All the experiments shown in this figure were carried out in 35 mM sodium acetate buffer, pH 5.3, 150 mM KCl.
FIGURE 3 |Global kinetic analysis of the IAPP aggregation reactions. (A) Double logarithmic plot of the average t1/2 vs the initial IAPP monomer concentration. The
slope of these points gives the scaling exponent γ. (B–D)Global fits to the normalised ThT fluorescence intensity as a function of time using models where (B) nucleation
and elongation occurs with no secondary pathways, (C) fragmentation is dominant, and (D) secondary nucleation is dominant. Note that the best fit of the IAPP
aggregation corresponds to the model where secondary nucleation is dominant.
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order of the dominant nucleation mechanism generating new
aggregates (Cohen et al., 2012). The scaling exponent for IAPP is
found to be γ ∼ −1.26 ± 0.05 (Figure 3A). The value of this scaling
exponent is reproducible between discrete batches of the peptide;
however, deviation of the absolute t1/2 values can be observed,
which may originate from errors in the estimates of the
concentration of IAPP (Supplementary Figure S1). A scaling
exponent of approximately −1.2 to −1.3 excludes aggregate
proliferation by fragmentation as a dominant mechanism, in
which case γ ≈ −0.5 is expected, i.e., a weaker monomer
dependence as new aggregates are generated by fibrils alone
(Cohen et al., 2012). Moreover, the scaling exponent for IAPP
is in the range of that obtained for Aβ42 (c  -1.3), which has
previously been shown to aggregate via a surface-catalysed
secondary nucleation mechanism (Cohen et al., 2013).
IAPP Aggregates via a Mechanism
Dominated by Surface-Catalysed
Secondary Nucleation
The kinetic traces of IAPP aggregation were analysed using the
AmyloFit platform (Meisl et al., 2016) to connect the macroscopic
measurements of protein aggregation to the microscopic
mechanisms using chemical kinetics. The aim of the analysis
is to describe the entire set of kinetic data at all different IAPP
monomer concentrations using a single rate law (Figures 3B–D).
The fitting results for IAPP show that the data are collectively best
described by a model in which the main source of new aggregates
is a process involving fibril surfaces catalysing the nucleation of
IAPP monomers (Figure 3D). Indeed, the results show excellent
agreement between this model and the experimental kinetic data
(Figure 3D). Conversely, when the data were fitted to other
aggregation mechanisms, i.e. nucleation-elongation (Figure 3B)
or nucleation-elongation and fragmentation (Figure 3C), they
were not well-described by the kinetics models.
The aggregation mechanism of IAPP was further investigated
by aggregation experiments of IAPP in the presence of preformed
seeds (Figure 4). For an aggregation process in which secondary
nucleation is the dominant process, addition of small amounts
(on the order of 1% or less) of preformed fibril seeds will result in
a significant reduction of t1/2. This phenomenon is not observed
in aggregation processes which include only primary nucleation
and elongation, since the elongation of the small quantity of seeds
would be within the noise level of the experiment and there would
not be a shift in t1/2 (Cohen et al., 2012). As shown in Figure 4, a
significant acceleration in the aggregation reaction is observed in
the presence of preformed seeds. The acceleration of aggregation
increases as a function of the seed concentration (Figure 4). In
fact, t1/2 shows a linear dependence on the logarithm of the seed
concentration, which is expected of self-seeding behaviour in the
presence of secondary pathways (Arosio et al., 2014) (Figure 4B).
The results also reveal that even low concentrations of seeds,
i.e., 0.5%, are sufficient to accelerate the reaction, which confirms
that secondary processes are involved in the aggregation
mechanism of IAPP. The elongation rate constant, k+, was
estimated by using the initial gradient of the highly seeded
data (33%) and the average fibril length determined from
cryo-TEM measurements, to be approximately 5.105 M−1s−1
(see materials and methods) (Meisl et al., 2014). Taken
together, the experimental and theoretical results reported here
reveal unambiguously that IAPP aggregates through a
mechanism governed by surface catalysed secondary nucleation.
The pH (5.5) selected for the present study mimics the
intragranular pH (5–6) of the insulin-secretory granule, where
IAPP is located (Hutton et al., 1982). While some of the IAPP will
be secreted from these granules, the data from experiments
performed at pH 7.5 (Supplementary Figures SI4, I5) are
better fitted if secondary nucleation is included, implying that
the mechanism we describe at pH 5.5 extends to neutral pH.
The results for IAPP aggregation presented here can be
compared to other peptides that have been shown to aggregate
via a mechanism dominated by secondary nucleation (Aβ40,
Aβ42 and α-synuclein) (Cohen et al., 2013; Buell et al., 2014;
Meisl et al., 2014). The scaling exponent γ of IAPP under native
conditions, pH 5.3 and an ionic strength of 183 mM, where its net
charge is close to +2 is in the same range as previously detected for
Aβ42 (determined under conditions where its net charge is close
to -3) (Figure 5). Future quantitative comparison at identical
FIGURE 4 | Aggregation of IAPP in the presence of preformed fibrils. (A) Kinetic profile of 5 µM IAPP in the absence or presence of increasing concentrations of
preformed fibril seeds. (B) t1/2 of the aggregation as observed from (A) as a function of the logarithm of the seed concentration.
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solution conditions and as a function of pH and salt to modulate
the influence of electrostatic interactions will provide additional
insights into the commonalities and specifics of the aggregation
mechanisms among different proteins and peptides.
IAPP Aggregation Generates Species That
Are Toxic to Insulinoma Cells
Three different cell biology assays were performed in order to
study the biological activity of species generated during the IAPP
aggregation reaction. Insulinoma cells were exposed to IAPP
samples taken at different time points of the aggregation
reaction (Figure 6). These samples included: 1) IAPP at the
start of the aggregation process, where it is mostly monomeric
(t0); 2) IAPP at the t1/2 of the aggregation process, where there is a
significant population of oligomers is expected to coexist with
monomers and fibrils; 3) IAPP at the end of the aggregation
process, 2.4 t1/2, where there are predominantly fibrillar species
(but a smaller fraction of both oligomers and monomers remains)
(Michaels et al., 2020). The ability of these samples, from the three
different time points in the aggregation time course, to cause
cellular dysfunction either by early or late cell toxicity readouts
were assessed.
The level by which the samples disrupted cellular membranes
and induced Ca2+ influx, which is widely regarded as a
phenomenon associated with the toxicity of aggregates
(Flagmeier et al., 2017), were measured after 30 min of
treatment as an early readout. The Fluo-4 calcium indicator
was used to measure intracellular calcium levels. A significant
increase in the amount of calcium influx for cells exposed to IAPP
samples at t1/2 and 2.4 t1/2 were observed (Figure 6C). These
results suggest that IAPP aggregation intermediates are able to
trigger Ca2+ influx within insulinoma cells.
The apoptotic marker Hoechst 33,342 was also used to
investigate the 30 min treated cell samples. Interestingly, a
significant increase in the signal were observed for the cells
treated with the t1/2 sample compared to the t0 sample
(Figure 6D). Also the 2.4 t1/2 sample showed an increased
signal i.e., the samples containing species other than
monomers shows an increase in cytotoxicity after 30 min
treatment.
The CellTiter-Glo luminescent assay was used to estimate the
viability of the cells by measuring the ATP levels produced by
metabolically active cells after a 24 h treatment by the three
different samples. A decrease in viability occurred in the cells
treated with the t1/2 sample (Figure 6E). The 24 h assay also
reveals that the t0 sample also decreased the cell viability, which
could be attributed to monomeric IAPP sample aggregating,
i.e., producing oligomers, during the course of the 24 h assay.
Taken together, these results show that only the t1/2 samples,
where oligomeric species are present at their maximum
concentration for a secondary nucleation driven reaction, are
able to both trigger significant calcium influx and cause a
significant decrease of cell viability.
FIGURE 5 | Schematic illustration of the aggregation reaction pathway of IAPP. Monomers initially aggregate through a primary pathway (primary nucleation and
elongation). Once a critical amount of fibrils has been formed, the catalytic nature of secondary nucleation becomes the dominant process in generating the oligomers in
the aggregation process. In the table, the rates of formation of aggregates through primary and secondary pathways are calculated for a 5 µM sample in 33 mM acetate,
150 mMKCl, pH 5.3. Rate constants of Aβ42 in 20 mM sodium phosphate, pH 8.0 and Aβ40 in 20 mM sodium phosphate, pH 7.4 are obtained from (Cohen et al.,
2013; Meisl et al., 2014).
Frontiers in Molecular Biosciences | www.frontiersin.org November 2021 | Volume 8 | Article 7574256
Rodriguez Camargo et al. IAPP Aggregation Mechanism and Toxicity
CONCLUSION
The results of this work reveal that the aggregation process of
recombinant IAPP under quiescent conditions is dominated by
secondary nucleation catalysed by fibril surfaces. Moreover, the
oligomeric species generated from secondary nucleation appear to
be significantly toxic to insulinoma cells. These results provide a
possible rationale for the association between the aggregation of
IAPP and the death of β-cells in diabetes type II. This study therefore
identifies IAPP oligomers as an important target for drug discovery
for diabetes type II, and indicates that the design of inhibitors of
secondary nucleation could be developed as a treatment to preserve
or restore the function of β-cells in this disease.
MATERIALS AND METHODS
Expression and Purification in E. coli Cells
The recombinant IAPP peptide (KCNTATCATQRLANFL
VHSSNNFGAILSSTNVGSNTY) was produced as described
FIGURE 6 | Toxicity measurements of cells exposed to IAPP samples from an ongoing aggregation reaction. (A) During the time course of aggregation, samples at
the beginning of the reaction where IAPP species aremonomeric (t0), at themiddle of the reaction where IAPP is ca. half monomeric and half fibrillar and low but significant
levels of oligomers are present (t1/2), and at the end of the reaction where samples aremostly fibrillar but some oligomers are still likely to be present (2.4 t1/2), are taken out
and incubated with insulinoma cells in order to assess their toxicity. (B) Representative images indicating either the fluorescence of Fluo-4 or Hoechst 33,342 of
insulinoma cells after treatment with IAPP species at different timepoints. (C) Fluorescence intensity of Fluo-4 indicating Ca2+ influx levels of cells treated with IAPP
species at different timepoints. (D) Fluorescence intensity of the apoptotic marker Hoechst 33,342 of cells treated with IAPP species at different timepoints. (E) Viability of
cells treated for 24 h with IAPP species at different timepoints assessed by means of the CellTiter-Glo assay.
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previously (Rodriguez Camargo et al., 2015) with the following
modifications. All expression media were supplemented with
ampicillin (Duchefa Biochemie A0104.0010) to a final
concentration of 50 μg/ml. Protein expression was induced
by adding IPTG to a final concentration of 0.4 mM. After
induction, the cultures were incubated at 20 C whilst
shaking at 200 rpm overnight in baffled flasks. Cultures were
harvested by centrifugation at 5,000 g. The resulting pellet from
1 L culture was resuspended in 25 ml of 20 mM HEPES,
0.1 mM EDTA, 2 M urea, 50 mM NaCl, pH 8. The eluate,
after the chitin step, containing the fusion protein leader-
IAPP was concentrated from 100 to 15 ml using 3 kDa
cutoff centrifugal filters (Amicon) where after the buffer
were changed by using six disposable PD 10 Desalting
Columns (GE Healthcare, 17-0851-01) to the standard
buffer (20 mM HEPES, 0.1 mM EDTA, 2 M urea, 50 mM
NaCl, pH 8.0) in parallel. The lyophilised fraction of IAPP
from the HPLC step was dissolved in 35 mM sodium acetate
buffer pH 5.3 keeping the concentration of peptide lower than
100 µM and oxidised by the addition hydrogen peroxide to a
final concentration of 3 mM and incubated for 6 h at 4 C after
which the peptide was again lyophilized.
Size-Exclusion Chromatography Before
Kinetics
The lyophilised powder was dissolved in 5 ml, 8 M urea, 35 mM
acetate and pH 5.3 to give an approximate protein concentration
of 70 μM, as determined by absorbance spectroscopy using ε280
 1615 L mol−1 cm−1. The solution was loaded onto a HiPrep 16/
60 Sephacryl S-100 HR (17,116,501 GE Healthcare) size
exclusion column and proteins were separated using a flow
rate of 1.0 ml/min. Fractions containing only monomeric IAPP
were combined, yielding 18.6 µM IAPP in 14 ml, aliquoted,
lyophilized and stored at -80 C for use in the kinetics
experiments.
Just prior to each kinetics experiment, the lyophilised peptide
was solubilised in 1 ml, 35 mM sodium acetate, pH 5.3, and
loaded onto a Tricorn 10/300™ GL Sephacryl S-100 HR size
exclusion column (17,061,201 GE Healthcare) equilibrated in the
same buffer. Fractions containing monomeric IAPP were
collected, combined, and kept on ice until use in the kinetics
experiments.
Discarded options for size-exclusion chromatography. Several
buffer components (urea, GuHCl), pH values (4.0, 5-0, 5.3, 5.5
and 6.0). NaAc concentrations (from 35 to 1.7 mM),
temperatures (above 4 C) and column types [Superdex 30
increase 10/300 GL (GE Healthcare), Superdex 75 increase 10/
300 GL (GE Healthcare)] were discarded during initial
optimisation of monomer isolation because they lead to loss of
more than 80% of the peptide, or the purity of the monomeric
sample was compromised.
SDS Polyacrylamide Gel Electrophoresis
Novex™ 10–20% Tricine Protein Gels, 1.0 mm (Invitrogen™
EC66255BOX) were used for the SDS-PAGE analyses. The
gels were run for 45 min at 150 V in Tris/tricine running
buffer (0.1 M Tris, 0.1 M tricine, 0.1% SDS, pH 8.25) and
stained with InstantBlue® Protein Stain (SKU: ISB1L
Expedeon).
Mass-Spectrometry Analysis
Monomer of oxidized IAPP was isolated using SEC in
30 mM acetic acid pH 5.3, dried under vacuum and
dissolved in 4 μl 0.1% Trifluoroacetic acid (TFA), 2%
acetonitrile (ACN). Matrix solution, 0.5 µl consisting of
5 mg/ml α-cyano-4-hydroxy cinnamic acid, 80% ACN,
0.1% TFA, were mixed with 1 µl sample and spotted on a
MALDI stainless steel plate. MS spectra were acquired using
a Autoflex Speed MALDI TOF/TOF mass spectrometer
(Bruker Daltonics, Bremen, Germany) in positive reflector
or positive linear mode. The observed mono-isotopic mass
of 3,900.9 Da corresponds to full-length oxidized and
amidated IAPP.
Aggregation Kinetic Assay
All samples were prepared in low-binding tubes (Axygen) on ice.
Monomeric IAPP in 35 mM acetate buffer pH 5.3 was mixed with
a 2.5 M stock solution of KCl and a 2 mM stock solution of ThT
(CalBiochem, purchased from Sigma-Aldrich, Product code
596,200, dissolved in H2O and filtered through a 200 nm filter
and concentration determined using absorbance) to a final
concentration of 33 mM acetate, 150 mM KCl, pH 5.3, 20 µM
ThT. Solutions were pipetted into wells of a 96-well Half Area
Black/Clear Flat Bottom PEGylated Polystyrene plate (Corning®
3,881), 80 µl per well in triplicates. The ThT fluorescence was
monitored through the bottom of the plate over time as a reporter
of the amount of aggregates formed using a plate reader
(FLUOstar Omega, FLUOstar Galaxy or FLUOstar, BMG
Labtech) equipped with 440 nm excitation filter and 480 nm
emission filter.
Seeded Aggregation Assays
Fibril seeds were prepared by adding a 5 µM IAPP solution in
33 mM acetate, 150 mM KCl, 20 μM ThT, pH 5.3, in the 96-well
plate and incubating the solution in the plate reader as described
above. The ThT fluorescence was monitored to ensure that the
aggregation reaction was complete before collecting the seeds.
The collected fibril seeds were added to monomer IAPP solutions
to final seed concentrations ranging from 0 to 33% of the
monomer concentrations (in monomer equivalents). The
solutions were pipetted in triplicate to the 96-well plates and
the aggregation process was followed by monitoring the ThT
fluorescence in the plate reader at 37 C under quiescent
conditions, as described above.
Integrated Rate Law
All analyses involving the determination of the midpoint of the
aggregation reaction (t1/2) and the global analysis of the kinetic
data were performed using the online Amylofit platform (Meisl
et al., 2016). For the global analysis of the kinetic data the
following rate law was used, which describes the IAPP species
distribution over time and allows for the inclusion of secondary
nucleation:
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and where [m]0 is the initial concentration of soluble monomers,
[M]0 and [M]∞ are the mass concentration of fibrils at the start
and the end of the reaction respectively, and [P]0 and [P]∞ are
the number concentration of aggregates at the start and end of the
reaction respectively; nc and n2 are the reaction orders relative to
the monomer of the primary and secondary nucleation pathways
respectively; k+, k2, and kn are the rate constants for elongation,
secondary nucleation, and primary nucleation, respectively. The
equations derived for models with fragmentation, have been
described previously (Meisl et al., 2016).
Cryo-Electron Microscopy
Fibrils were collected after reaching the plateau phase in the
aggregation process and analysed by cryogenic transmission
electron microscopy (TEM). The samples were loaded as a
liquid film on a lacey carbon filmed cooper grid (01881F
Lacey F/C, 200 mech Cu; PELCO No.160). A layer of sample
less than 300 nm thick was produced on the grid by blotting
the extra liquid away at the back of the grid using a filter
paper, followed by flash freezing the grid in liquid ethane and
whereafter it was stored in liquid nitrogen. The grid
preparation was carried out in a controlled environment
vitrification system to ensure the stable temperature and
humidity in order to maintain the original state of the
sample. Images were recorded using a 120 kV electron
microscope (Philips CM120 BioTWIN Cryo) with a CCD
camera. The size of the fibrils, for statistical purposes, were
analysed using ImageJ (Schneider et al., 2012).
Determination of Elongation Rate Constant
The estimation of the elongation rate constant was performed
as described previously (Meisl et al., 2014, 2017). Firstly, the
fibril sizes were estimated from length and thickness
measurements based on cryo-EM images (Supplementary
Figure S6). The average length was determined to be 900 ±
400 nm, and the cross area 80 ± 20 nm2. Assuming a
protein density of 1.3 g/ml and the molecular mass of
3,906 Da for the IAPP monomer, each fibril was estimated
to consist of approximately 14,400 monomers. Subsequently,
using the results of the strongly seeded aggregation
(33% seeds), the initial gradient, dM/dt/t0  2k+m(0)P(0)
was derived. To estimate the number of seed fibrils, P (0), the
mass concentration of seed fibrils (inmonomer equivalents), M (0),
which is known, was divided by the number of monomers per seed
fibrils. The elongation rate constant was then determined to be
approximately 5·105 M−1s−1, within a factor of 3, based on the
heterogeneous length and thickness distribution in the fibril
samples.
Cell Cultures
INS-1 832/13 rat insulinoma cells (Merck KGaA, Darmstadt,
Germany) were cultured in RPMI-1640 (Thermofisher,
United Kingdom) supplemented with 2 mM L-glutamine,
1 mM sodium pyruvate, 10 mM HEPES, 0.05 mM
β-mercaptoethanol and 10% heat-inactivated fetal bovine
serum. The cell cultures were maintained at 37 C in a 5.0%
CO2 humidified atmosphere and grown until 80% confluence
for a maximum of 20 passages.
Cell Viability Assay
Cell viability was measured using the CellTiter-Glo Luminescent
Cell Viability Assay (Promega) according to the manufacturer’s
instructions. Briefly, the cells were plated into a white opaque 96-
well plate and treated for 24 h with samples containing 5 µM
IAPP from an aggregation time course (6 replicates per
condition). The final concentration of IAPP was 1.25 µM
(monomer equivalent). Luminescence values were measured
using a plate reader (ClarioStar Omega BMG Labtech,
Aylesbury, United Kingdom), and cell viability was expressed
as a percentage vs untreated cells (taken as 100%).
Calcium Release Assay
The cytosolic calcium ion (Ca2+) levels were measured by
exposing the INS-1 832/13 cells loaded with 2.0 μM Fluo4-AM
to samples containing 5 µM IAPP taken at different time points of
an aggregation reaction (3 replicates per time-point). The final
concentration of IAPP was 2.5 µM (monomer equivalent). The
emitted fluorescence was recorded after excitation at 488 nm
using the fluorescence microscope Cytation5 Cell Imaging Reader
and quantified by means of the Gen5 Data Analysis software
(BioTek Instruments, Winooski, VT).
Hoechst 33,342 Staining Assay
INS-1 832/13 cells were treated with samples containing 5 µM
IAPP from an aggregation reaction (3 replicates per time-point).
The final concentration of IAPP was 2.5 µM IAPP. Cells were
stained with the apoptotic marker Hoechst 33,342. The emitted
fluorescence was recorded after excitation at 350 nm using the
fluorescence microscope Cytation5 Cell Imaging Reader and
quantified by means of the Gen5 Data Analysis software
(BioTek Instruments, Winooski, VT).
Statistical Analysis
For cellular assays, comparisons between groups were performed
using one-way ANOVA followed by Bonferroni’s multiple
comparison test. A p-value lower than 0.05 was considered
statistically significant.
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